STAT August 5, 2024
Morning! Today, we discuss the maneuverings of two interesting women in biotech: Verily alum Amy Abernethy and 23andMe CEO Anne Wojcicki. Also, we explore the dangers of off-brand GLP-1s, and see FDA advisers vote in favor of a Niemann-Pick drug.
The danger of alternate GLP-1 sources
Shortages of GLP-1 drugs have prompted patients to rely on risky sources for these medicines, like illegal online pharmacies that don’t require prescriptions. A new JAMA paper found that semaglutide from such sites can be contaminated with bacteria, and contain far more of the drug than labeled.
The FDA has previously issued warnings about compounded GLP-1s, but that hasn’t dissuaded patients from pursuing non-branded versions of these drugs. That said, the supply of drugs...
Today's Sponsors
Today's Sponsor